Allogene Therapeutics ALLO Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's cash, cash equivalents, and marketable securities?
- Allogene Therapeutics (ALLO) reported cash, cash equivalents, and marketable securities of $0 in Q1 2026.
- What is the long-term trend for Allogene Therapeutics's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's cash, cash equivalents, and marketable securities has grown at a -100.0% compound annual growth rate (CAGR), from $5M to $0.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.